Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
CPRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$19.05 - $26.58
Previous CloseN/A
Volume328.11K
Average Volume (3M)1.55M
Market Cap
$2.39B
Enterprise Value$2.12B
Total Cash (Recent Filing)$652.80M
Total Debt (Recent Filing)$2.99M
Price to Earnings (P/E)11.8
Beta0.85
Next Earnings
Nov 05, 2025EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.41
Shares Outstanding122,391,010
10 Day Avg. Volume1,565,845
30 Day Avg. Volume1,553,360
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue3.79
Enterprise Value/Gross Profit4.51
Enterprise Value/Ebitda7.71
Forecast
1Y Price Target
$33.00Price Target Upside69.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Guideline UpdatesThe inclusion of VGCC antibody testing and the recommendation that amifampridine (Firdapse) should be considered as a treatment for SCLC patients with LEMS in the NCCN guidelines further strengthens CPRX's efforts to accelerate diagnosis and drive Firdapse adoption in oncology.
Market AdoptionBreadth is expanding with a high percentage of top DMD Centers of Excellence and unique healthcare providers having submitted at least one enrollment form, suggesting strong support and adoption in the market.
Revenue PerformanceCatalyst's commercial business remains robust with total product revenues exceeding consensus expectations.
Bears Say
Generic Competition RiskManagement flagged risk of additional generics as rationale for conservative FY25 guide.
Revenue ShortfallFirdapse revenue missed consensus due to underestimated impact from insurance claims disruption.
Catalyst Pharma News
CPRX FAQ
What was Catalyst Pharma’s price range in the past 12 months?
Catalyst Pharma lowest stock price was $19.05 and its highest was $26.58 in the past 12 months.
What is Catalyst Pharma’s market cap?
Catalyst Pharma’s market cap is $2.39B.
When is Catalyst Pharma’s upcoming earnings report date?
Catalyst Pharma’s upcoming earnings report date is Nov 05, 2025 which is in 36 days.
How were Catalyst Pharma’s earnings last quarter?
Catalyst Pharma released its earnings results on Aug 06, 2025. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.392 by $0.018.
Is Catalyst Pharma overvalued?
According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued.
Does Catalyst Pharma pay dividends?
Catalyst Pharma does not currently pay dividends.
What is Catalyst Pharma’s EPS estimate?
Catalyst Pharma’s EPS estimate is 0.33.
How many shares outstanding does Catalyst Pharma have?
Catalyst Pharma has 122,391,010 shares outstanding.
What happened to Catalyst Pharma’s price movement after its last earnings report?
Catalyst Pharma reported an EPS of $0.41 in its last earnings report, beating expectations of $0.392. Following the earnings report the stock price went down -9.867%.
Which hedge fund is a major shareholder of Catalyst Pharma?
Currently, no hedge funds are holding shares in CPRX
Catalyst Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (69.06% Upside)
$33.00 (69.06% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 561.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $987.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.15%
12-Months-Change
Fundamentals
Return on Equity
28.49%
Trailing 12-Months
Asset Growth
37.59%
Trailing 12-Months
Company Description
Catalyst Pharma
Catalyst Pharmaceuticals, Inc. (CPRX) is a biopharmaceutical company focused on developing innovative therapies for people with rare neurological diseases. The company primarily operates in the pharmaceutical sector and is known for its flagship product, Firdapse (amifampridine), which is approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) and is being explored for other rare conditions. Catalyst Pharma aims to address unmet medical needs through its specialized drug development and commercialization efforts.
CPRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with significant revenue growth across key products, particularly FIRDAPSE and AGAMREE. However, challenges remain with the decline in FYCOMPA revenue due to generic competition and increased operational expenses. The strategic initiatives and strengthened leadership team position Catalyst for sustained growth, though uncertainties in patent litigation may impact future performance.View all CPRX earnings summariesCPRX Stock 12 Month Forecast
Average Price Target
$33.00
▲(69.06% Upside)
Technical Analysis
Amicus
―
Travere Therapeutics
―
Ocular Therapeutix
―
ImmunityBio
―
Liquidia Technologies
―
Ownership Overview
6.18% Insiders
17.78% Mutual Funds
16.69% Other Institutional Investors
35.13% Public Companies and
Individual Investors